Federal Research Public Access Act

Affluent Medical : Coverage initiation by Kepler Cheuvreux.

Retrieved on: 
Thursday, April 14, 2022
Kepler, Bird, Federal Research Public Access Act, Kepler Cheuvreux, Death, Decision-making, ISIN, Kalio, Trial of the century, Heart, Degenerative disease, China Investment Securities, Company, Urinary incontinence, Regulatory News Service, Medical imaging, Medtech

Affluent Medical : Coverage initiation by Kepler Cheuvreux.

Key Points: 
  • Affluent Medical : Coverage initiation by Kepler Cheuvreux.
  • Affluent Medical (ISIN code: FR0013333077 - Ticker: AFME), a French medtech specialising in the international development and industrialisation of innovative medical prostheses, at a clinical stage, to treat urinary incontinence and mitral valve pathology, announces today that Kepler Cheuvreux has initiated coverage of the stock.
  • Affluent Medical now benefits from Kepler Cheuvreux' coverage with the publication of a financial note entitled "Kill three birds with one stone".
  • Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas.

Emmaus Life Sciences' Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Haematology

Retrieved on: 
Friday, March 4, 2022
Manchester Central Library, Chest pain, Mark (given name), Patient, End organ damage, Fortification, Adult, Food and Drug Administration, Birth, Society, Emma Yhnell, Food, OTCQX, Safety, Extremities, FDA, Science, Plasma, Indigestion, Manchester Central, African Americans, Blood, Abdominal pain, Nausea, Headache, Multimedia, National Centre for Disease Control, Centers for Disease Control and Prevention, Pain, BSH, Federal Research Public Access Act, Sickle cell disease, Diverticulosis, Blueprint, Splenomegaly, Constipation, Cough, Sickle, Hispanic and Latino Americans, Disability in Canada, Center, Incidence, National academy, SCD, Back pain, Pharmaceutical industry, Online shopping, Vaccine, Research, Glutamine

Delegates also have the option to save the posters and email the submitting author to ask questions.

Key Points: 
  • Delegates also have the option to save the posters and email the submitting author to ask questions.
  • Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
  • 2Source: Committee on Addressing Sickle Cell Disease A Strategic Plan and Blueprint for Action -- National Academy of Sciences Press, 2020.
  • Throughout the Middle East North Africa region, Emmaus estimates that there are approximately 225,000 sickle cell disease patients that could potentially be treated with Endari.

TurbineOne Awarded Air Force Contract to Deploy New Machine Learning Capability to Frontlines

Retrieved on: 
Friday, February 11, 2022
Data Management, Public Policy, Government, Defense, Technology, Software, Homeland Security, Contracts, The, Small Business Innovation Research, Small business, U.S. Department of Commerce Office of Security, SBIR, Department, Perception, U.S. Department of Defense Strategy for Operating in Cyberspace, Amazon, Public sector, Federal Research Public Access Act, Forward-looking infrared, Press release, VFA-14 (U.S. Navy), AFRL, Google, Commerce, Machine learning, Technology, Air Force Research Laboratory, United, Air force, AFWERX, AFSOC, Software, Research, Multimedia, Investment, Program, Pentagon, Management, TurbineOne, AFWERX, TURBINEONE, AFWERX

TurbineOne, the frontline perception company, was awarded a Small Business Innovation Research ( SBIR ) contract to advance its machine learning capabilities and deploy its software with the United States Air Force.

Key Points: 
  • TurbineOne, the frontline perception company, was awarded a Small Business Innovation Research ( SBIR ) contract to advance its machine learning capabilities and deploy its software with the United States Air Force.
  • The specific offices within the Air Force that made the SBIR award to TurbineOne are the Air Force Research Laboratory ( AFRL ) and AFWERX .
  • TurbineOne plans to successfully deliver to its customer and end-users within one year of the contract award.
  • We leverage Machine Learning to provide frontline perception that empowers first-responders and warfighters with greater situational awareness.

Accern and LPA Partner to Deliver Enhanced AI-Powered Investment Research for Capital Markets

Retrieved on: 
Tuesday, February 8, 2022
News, Industry, Standard German phonology, Growth, AI, OTC, Federal Research Public Access Act, Consultant, Face, Research, Solution, DACH, Software, Compliance, Risk, Efficiency, Technology, ESG, CEO, Adoption, Mark (given name), Entrepreneurship, LPA, Documentation, Partnership, Medical device

The partnership will drive additional growth for both firms by combining LPA's deep capital markets expertise with Accern's platform, driving the adoption of AI-powered investment research among clients in North America, Europe, and Asia.

Key Points: 
  • The partnership will drive additional growth for both firms by combining LPA's deep capital markets expertise with Accern's platform, driving the adoption of AI-powered investment research among clients in North America, Europe, and Asia.
  • LPA provides technical innovations and consulting services for the capital market industry, which optimize processes and ensure regulatory compliance.
  • "Accern continues to identify innovative approaches to partnerships that enable us to stay at the forefront of investment research insights in the financial services industry," said Kumesh Aroomoogan, Co-Founder and CEO of Accern.
  • "Working with a capital markets technology leader like LPA will drive wider AI adoption among financial services firms around the world.

Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Tuesday, December 14, 2021
National academy, Diverticulosis, Centers for Disease Control and Prevention, Food, Headache, FDA, Blood, Federal Research Public Access Act, Sickle cell disease, Science, Pain, Cough, OTCQX, RBC, Adult, Back pain, Incidence, Disability in Canada, Birth, Hispanic and Latino Americans, Constipation, End organ damage, Blueprint, Extremities, Hydroxycarbamide, Center, Safety, Trial of the century, Patient, Exhibition, Congress Center, Nausea, Therapy, Indigestion, Red blood cell, Food and Drug Administration, Multimedia, ASH, Emma Yhnell, Chest pain, SCD, Splenomegaly, Society, African Americans, Georgia World Congress Center, Abdominal pain, Sickle, Pharmaceutical industry, Vaccine, Glutamine

The multicenter phase 3 trial enrolled a total of 230 patients, randomized 2:1, to receive Endari (152 patients) or placebo (78 patients).

Key Points: 
  • The multicenter phase 3 trial enrolled a total of 230 patients, randomized 2:1, to receive Endari (152 patients) or placebo (78 patients).
  • Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
  • The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.
  • 2Source: Committee on Addressing Sickle Cell Disease A Strategic Plan and Blueprint for Action -- National Academy of Sciences Press, 2020.

Emmaus Life Sciences' Data on Endari® Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Meeting & Exhibition

Retrieved on: 
Monday, December 6, 2021
Patient, African Americans, Centers for Disease Control and Prevention, Birth, National academy, Federal Research Public Access Act, Chest pain, Safety, SCD, Indigestion, Nausea, Splenomegaly, Blood, Sickle cell disease, End organ damage, Hispanic and Latino Americans, Exhibition, Headache, Cough, Sickle, Pain, Blueprint, Abdominal pain, Extremities, Food and Drug Administration, OTCQX, Back pain, Emma Yhnell, Congress Center, Adult, Incidence, ASH, Disability in Canada, Science, Society, Georgia World Congress Center, Constipation, FDA, Diverticulosis, Multimedia, Center, Food, Pharmaceutical industry, Vaccine

Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Key Points: 
  • Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
  • The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.
  • There are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally.
  • 2Source: Committee on Addressing Sickle Cell Disease A Strategic Plan and Blueprint for Action -- National Academy of Sciences Press, 2020.

IQM's Q-Exa Consortium Selected to Integrate German Quantum Computer Into HPC Supercomputer for the First Time

Retrieved on: 
Monday, November 15, 2021
Hardware, Science, Research, Technology, Software, Computer, Industry, Science, LRZ, HPC, VTT, Director, BMBF, Acceleration, QIC, Atos, CEO, European Union, Gottfried Wilhelm Leibniz, Technology, Union, IQM, Multimedia, Quantum, Federal, Participatory design, Board, Chemistry, Environment, MQV, Solution, Laboratory, Federal Research Public Access Act, Federal Ministry of Education and Research (Germany), Leibniz Supercomputing Centre, Biology, Education, Physics, Microscope, Renewable energy

IQM Quantum Computers has been selected to provide a quantum computing system that will be integrated into an HPC supercomputer to create an accelerator for future scientific research.

Key Points: 
  • IQM Quantum Computers has been selected to provide a quantum computing system that will be integrated into an HPC supercomputer to create an accelerator for future scientific research.
  • This will be the first time that a gate-based quantum system will be coupled with an HPC system, making quantum acceleration of HPC applications a reality.
  • To meet this challenge, HPC centers around the world are looking for ways to integrate quantum accelerators into their computing infrastructure.
  • The new Co-Design lab will accelerate the path to self-sustaining quantum computing, the so-called quantum advantage, through industry partnerships.